



April 26, 2023
JCR Pharmaceuticals Co., Ltd.

Translation

Notice Regarding Partial Amendment to the Articles of Incorporation and Nomination of a Candidate to the Board of Directors

April 26, 2023 -- JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, “JCR”) announced that the Board of Directors meeting held today resolved a proposal for partial amendment to its Articles of Incorporation and a proposal regarding nomination of a candidate for its Board of Directors to be presented before JCR’s Ordinary General Meeting of Shareholders scheduled in June 2023.

The appointment of a new member of the Board will be subject to approval at the Ordinary General Meeting of Shareholders.

1. Partial Amendment to the Articles of Incorporation

(1) Reason for the amendment

The Company proposes to increase the maximum number of directors from eleven (11) to twelve (12) to further strengthen and enhance the management oversight framework and facilitate business expansion and globalization.

(2) Details of amendment

Details of the amendment is as follows. The amended part is underlined.

Current Articles of Incorporation	Proposed amendment
(Number of Directors) Article 19: The number of directors shall not exceed <u>eleven (11)</u> .	(Number of Directors) Article 19: The number of directors shall not exceed <u>twelve (12)</u> .

(3) Schedule

Date for the Ordinary General Meeting of Shareholders to amend the Articles of Incorporation

June 21, 2023 (planned)

Effective date of the amendments to the Articles of Incorporation

June 21, 2023 (planned)

2. Candidate for Outside Director

Name	Marc Dunoyer	
Career	Oct. 1999	Representative Director Vice President, GlaxoWellcome KK
	Mar. 2000	Representative Director President, GlaxoWellcome KK
	Jan. 2001	Representative Director President, GlaxoSmithKline KK
	Mar. 2003	Corporate Executive Team Member, GlaxoSmithKline PLC
	May 2008	Regional President Asia Pacific & Japan, GlaxoSmithKline PLC
	Jan. 2010	Representative Director Chairman, GlaxoSmithKline KK
	Feb. 2010	Foundational Global Head of Rare Diseases Unit, GlaxoSmithKline PLC
	Jun. 2010	Outside Director, JCR Pharmaceuticals Co., Ltd.
	Apr. 2013	Resigned as Outside Director, JCR Pharmaceuticals Co., Ltd.
	Jun. 2013	Executive Vice President, Global Portfolio & Product Strategy, AstraZeneca PLC
	Nov. 2013	Member of the Board of Directors and Executive Director and Chief Financial Officer, AstraZeneca PLC Chairman of AstraZeneca KK (Current)
	Jun. 2018	Member of the Board of Directors, Orchard Therapeutics PLC (Current)
	Aug. 2021	Chief Executive Officer, Alexion, AstraZeneca's Rare Disease Group (Current) Chief Strategy Officer, AstraZeneca Group (Current)

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 48-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II (Hunter syndrome), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the

legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.

This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.

Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###